New guidelines from the International Antiviral Society recommend antiretroviral therapy for all HIV-infected patients, an expanded list of initial regimens, and less-frequent laboratory monitoring, as well as offer a nuanced discussion of treatment for experienced patients.
Sponsoring Organization: International Antiviral Society–USA (IAS-USA)Target Population: Clinicians who treat HIV-infected patients
Background and Objective
This guideline updates recommendations last made in 2012.
Key Recommendations
Antiretroviral therapy (ART) is recommended for all HIV-infected patients, including those with acute HIV infection—but not yet for elite controllers.
In patients with opportunistic infections and AIDS-defining illnesses, including cancers, ART should be started as soon as possible, usually within 2 weeks of diagnosis. In patients with cryptococcal meningitis, recent data suggest a slight delay may be warranted.
Initial regimens should include two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs; aba…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)